Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Presentation THT 2025

Myeloperoxidase Inhibition in Patients With Ischemic or Non-Ischemic Cardiomyopathy and Heart Failure With Reduced Ejection Fraction (MYSTERY-HF)

Presenter: Simon Braumann

February 12, 2025

Presentation TCT 2024

Final Results of the Novel Healing-Targeted DES With Synchronized Antiproliferative Drug Delivery to Target Smooth Muscle Cell Proliferation After DES Implantation in Coronary Artery Disease: 5-Year Results of the PIONEER III Trial

Presenter: Thomas Sharp

October 28, 2024

Presentation THT 2024

CMR in Ischemic Cardiomyopathy

Presenter: Jonathan Weinsaft

March 05, 2024

Presentation THT 2024

Alternative Advanced Therapy: Case of Cardiac Contractility Modulation in Stage D Ischemic Cardiomyopathy

Presenter: Daniel Asemota

March 05, 2024

Presentation THT Abstracts 2024

Interim Results from Adaptive Randomized Controlled Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure due to Reduced Left Ventricular Ejection Fraction (HFrEF)

Presenter: Amish Raval

March 04, 2024

Presentation THT Abstracts 2024

First in Man CardiALLO NK1R+ MSC Phase I/II Trial in Ischemic NYHA II and III HFrEF

Presenter: Carl Pepine

March 04, 2024

Presentation THT Abstracts 2024

Three-Dimensional Morphological Analysis por Percutaneous Closure Candidate Selection and In-Hospital Mortality Prediction in Ischemic Ventricular Septal Ruptures

Presenter: Eduardo Arias

March 04, 2024

Presentation TCT 2023

TCT 741: Clinical Outcomes of Ischemic Cardiomyopathy vs. Non-Ischemic Cardiomyopathy in Women with Left Ventricular Assist Device

Presenter: Priyadarshini Dixit

October 25, 2023

Presentation THT 2023

Left ventricular reconstruction compared to optimal medical therapy in patients with ischemic cardiomyopathy

Presenter: Oleg Polonetsky

March 21, 2023

Presentation THT 2023

The Role of Guideline Directed Medical Therapy in Functional Improvement after Hybrid Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

Presenter: Romy Hegeman

March 21, 2023

Presentation THT 2023

MCS strategies guided by ischemic vs. non-ischemic etiology and HF clinical phenotyping

Presenter: Rachna Kataria

March 21, 2023

Presentation TCT 2022

TCT 348: Evaluating improvement in regional left ventricular function after hybrid minimally invasive left ventricular reconstruction in ischemic cardiomyopathy: CT- or MRI-based inward displacement to overcome current shortcomings in imaging

Presenter: Romy Hegeman

September 18, 2022

Presentation The Structural Heart Disease Summit 2018

Early Clinical Experience With Hybrid Transcatheter Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

Presenter: Patrick Klein

June 22, 2018

Presentation TCT 2017

Preliminary Results of Hybrid, Less-Invasive Left Ventricular Reshaping for Ischemic Cardiomyopathy the St. Antonius Hospital Experience

Presenter: Daniel Burkhoff, Samir R. Kapadia, Patrick Klein

November 01, 2017

Presentation CHIP Seattle 2017

Ischemic Cardiomyopathy: Medical Therapy and Devices

Presenter: Ryan C. Martin

August 10, 2017

Presentation TCT 2016

LV Volume Reduction in Post-AMI, Ischemic Heart Failure Patients

Presenter: Oscar A. Mendiz, Giora Weisz, Horst Sievert

October 30, 2016

Presentation ESC 2016

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

Presenter: Javed Butler

August 28, 2016

Presentation

STOP HF: Changes in Ventricular Remodeling and Clinical Status During the Year After SDF-1 Gene Therapy in Chronic Ischemic Heart Failure Patients

Presenter: ES. Chung

June 22, 2015

Advertisement

Myeloperoxidase Inhibition in Patients With Ischemic or Non-Ischemic Cardiomyopathy and Heart Failure With Reduced Ejection Fraction (MYSTERY-HF)

Final Results of the Novel Healing-Targeted DES With Synchronized Antiproliferative Drug Delivery to Target Smooth Muscle Cell Proliferation After DES Implantation in Coronary Artery Disease: 5-Year Results of the PIONEER III Trial

CMR in Ischemic Cardiomyopathy

Alternative Advanced Therapy: Case of Cardiac Contractility Modulation in Stage D Ischemic Cardiomyopathy

Interim Results from Adaptive Randomized Controlled Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure due to Reduced Left Ventricular Ejection Fraction (HFrEF)

First in Man CardiALLO NK1R+ MSC Phase I/II Trial in Ischemic NYHA II and III HFrEF

Three-Dimensional Morphological Analysis por Percutaneous Closure Candidate Selection and In-Hospital Mortality Prediction in Ischemic Ventricular Septal Ruptures

TCT 741: Clinical Outcomes of Ischemic Cardiomyopathy vs. Non-Ischemic Cardiomyopathy in Women with Left Ventricular Assist Device

Left ventricular reconstruction compared to optimal medical therapy in patients with ischemic cardiomyopathy

The Role of Guideline Directed Medical Therapy in Functional Improvement after Hybrid Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

MCS strategies guided by ischemic vs. non-ischemic etiology and HF clinical phenotyping

TCT 348: Evaluating improvement in regional left ventricular function after hybrid minimally invasive left ventricular reconstruction in ischemic cardiomyopathy: CT- or MRI-based inward displacement to overcome current shortcomings in imaging

Early Clinical Experience With Hybrid Transcatheter Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

Preliminary Results of Hybrid, Less-Invasive Left Ventricular Reshaping for Ischemic Cardiomyopathy the St. Antonius Hospital Experience

Ischemic Cardiomyopathy: Medical Therapy and Devices

LV Volume Reduction in Post-AMI, Ischemic Heart Failure Patients

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

STOP HF: Changes in Ventricular Remodeling and Clinical Status During the Year After SDF-1 Gene Therapy in Chronic Ischemic Heart Failure Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content